Adverse event reporting information can be found at the bottom of the page

Asthma

You are here: / Asthma

Now licensed across all treatment steps1

WockAir Single
Asthma - Steps 1 and 2

WockAIR® 160/4.5mcg is the only generic ICS/formoterol inhaler licensed across all treatment steps for AIR-only and MART1

WockAIR® is bioequivalent to the originator Symbicort Turbohaler based on 80-125% bioequivalence limits for AUC, Cmax, and standard flow parameters8

This means that patients at all levels of asthma severity can benefit from:

  • reduced risk of asthma exacerbations compared to SABA containing regimens 1-4
  • A simple SABA free inhaled regimen– your patients will only need one inhaler. 1,5
  • A patient and carbon friendly device6,7

And the NHS can benefit from 32% acquisition cost savings versus Symbicort:

WockAir Pricing

Find out more about WockAIR®’s place in asthma therapy

Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/

Adverse events should also be reported to Wockhardt UK. Please contact us or email us at drug.safety@wockhardt.co.uk

REFERENCES

1. WockAIR® Summary of Product Characteristics

2. Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018; 319: 1485–1496.

3. Beasley R, DSc; Harrison T, Peterson S et al. Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled Asthma: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(3):e220615. doi:10.1001/jamanetworkopen.2022.0615

4. Crossingham I et al. Cochrane Database Syst Rev 2021; 5(5): CD013518

5. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023. Updated July 2023. Available from ginasthma.org

6. Virchow JC, Weuthen T, Harmer QJ, Jones S. Identifying the features of an easy-to-use and intuitive dry powder inhaler for asthma and chronic obstructive pulmonary disease therapy: results from a 28-day device handling study, and an airflow resistance study. Expert Opin Drug Deliv. 2014;11(12):1849–57

7. Janson C, et al. Thorax 2020;75:82–84. doi:10.1136/thoraxjnl-2019-213744. Carbon footprint impact of the choice of inhalers for asthma and COPD

8. Wockhardt data on file

9. MIMS May 2025

ABBREVIATIONS

AIR-anti-inflammatory reliever; AUC- area under curve; MART – Maintenance and Reliever Therapy; ICS- inhaled corticosteroid; SABA -short acting beta agonist

*Symbicort and Turbohaler are registered trademarks of AstraZeneca AB
** DuoResp and Spiromax are registered trademarks of Teva Pharmaceuticals Europe
***Fobumix and Easyhaler are registered trademarks of Orion Pharma UK Limited
†WockAIR* is a registered trademark or Wockhardt BIO AG

This site is intended for UK Healthcare Professionals.
Contact Us | Cookies and Privacy Policy | Terms of and Conditions of Use | Sitemap | PIL | Pharmacovigilance Privacy Notice
Job code: AIR06/25 July 2025